Drug intelligence / Profile preview

ZL-1503

Development stage: Phase 1
Lead developer: Zai Lab
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZL-1503 is a bispecific antibody developed by Zai Lab that targets both interleukin 13 (IL-13) and interleukin 31 (IL-31) pathways. It is designed to inhibit both inflammatory and pruritogenic signaling, which are implicated in moderate-to-severe atopic dermatitis and other diseases driven by IL-13 and IL-31. The drug features an extended serum half-life for sustained activity. Preclinical data show that intravenous administration of ZL-1503 can completely inhibit IL-13/IL-31 signaling, with the aim of providing improved efficacy over current therapies that only partially address these pathways[1][2][4][5][8].

Targets

IL31RA (IL-31 receptor alpha)IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on ZL-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-1503.

Explore the full profile